We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
26
UnitedHealth
UNH
$382B
$50.3M 0.64%
203,332
-8,966
-4% -$2.29M
T icon
27
AT&T
T
$165B
$49.4M 0.63%
1,909,585
+26,059
+1% +$599K
PEP icon
28
PepsiCo
PEP
$186B
$48M 0.61%
365,068
+177,049
+94% +$20.2M
ORCL icon
29
Oracle
ORCL
$331B
$46.5M 0.6%
842,543
+33,300
+4% +$1.7M
ABBV icon
30
AbbVie
ABBV
$458B
$45.7M 0.58%
566,513
+19,159
+4% +$1.57M
BRK.B icon
31
Berkshire Hathaway Class B
BRK.B
$1.07T
$45.6M 0.58%
192,880
-17,439
-8% -$3.52M
ABT icon
32
Abbott
ABT
$180B
$45.2M 0.58%
565,751
-46,893
-8% -$3.49M
GOOG icon
33
Alphabet (Google) Class C
GOOG
$3.9T
$45.1M 0.58%
769,100
+76,160
+11% +$4.27M
TSM icon
34
TSMC
TSM
$2.09T
$44.5M 0.57%
1,085,505
+499,819
+85% +$19.1M
PYPL icon
35
PayPal
PYPL
$49.5B
$43.3M 0.55%
417,026
-62,295
-13% -$5.9M
CRM icon
36
Salesforce
CRM
$134B
$43M 0.55%
271,420
-1,884
-0.7% -$292K
INCY icon
37
Incyte
INCY
$23.5B
$42.5M 0.54%
493,935
+28,413
+6% +$2.31M
C icon
38
Citigroup
C
$222B
$42.1M 0.54%
623,099
+43,554
+8% +$2.7M
AXP icon
39
American Express
AXP
$223B
$41.6M 0.53%
368,832
+6,824
+2% +$717K
JPM icon
40
JPMorgan Chase
JPM
$939B
$41.6M 0.53%
411,010
-99,686
-20% -$10.3M
BMRN icon
41
BioMarin Pharmaceuticals
BMRN
$11.5B
$40.9M 0.52%
459,852
– –
ARRY
42
DELISTED
Array Biopharma Inc
ARRY
$39.1M 0.5%
1,605,480
-73,230
-4% -$1.52M
ROK icon
43
Rockwell Automation
ROK
$51.4B
$39.1M 0.5%
222,553
+14,805
+7% +$2.52M
EMR icon
44
Emerson Electric
EMR
$82.9B
$37.4M 0.48%
545,699
+211,102
+63% +$13.9M
AVGO icon
45
Broadcom
AVGO
$1.82T
$37.2M 0.48%
1,235,640
-10,200
-0.8% -$277K
TAL icon
46
TAL Education Group
TAL
$5.71B
$34.9M 0.45%
966,000
+423,000
+78% +$13.7M
MA icon
47
Mastercard
MA
$477B
$34.2M 0.44%
145,370
-15,057
-9% -$3.24M
INTC icon
48
Intel
INTC
$466B
$32.6M 0.42%
564,891
-261,919
-32% -$13.3M
IONS icon
49
Ionis Pharmaceuticals
IONS
$9.35B
$31.9M 0.41%
393,200
+144,000
+58% +$9.29M
AERI
50
DELISTED
Aerie Pharmaceuticals
AERI
$28.7M 0.37%
604,800
+126,000
+26% +$5.55M
1
2
3 4 5

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.